AlzBiomarker
MCI-AD vs MCI-Stable: neurogranin (CSF)
Meta-analysis Results: Baseline levels of the synaptic protein neurogranin were significantly higher in people with mild cognitive impairment who went on to develop Alzheimer’s dementia than in those who did not decline at follow-up. Neurogranin is a relatively new biomarker candidate, and only four studies could be included in the meta-analysis (effect size = 1.542, p = 0.00299).

